Adverse Effects of Nonsystemic Steroids (Inhaled, Intranasal, and Cutaneous): a Review of the Literature and Suggested Monitoring Tool

Current Allergy and Asthma Reports

Volumn 16, Issue 6, 2016, Pages

  Gupta, Ratika ^a   Fonacier, Luz S ^a,b  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

Adverse reaction to topical corticosteroids; Inhaled corticosteroids; Monitoring corticosteroids; Nasal corticosteroids; Steroid side effects; Topical corticosteroids

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; CICLESONIDE; FLUTICASONE; FLUTICASONE FUROATE; FLUTICASONE PROPIONATE; HYDROCORTISONE; MOMETASONE FUROATE; NEDOCROMIL; PLACEBO; STEROID; TRIAMCINOLONE ACETONIDE;

ACNE; ADRENAL CORTEX INSUFFICIENCY; ALLERGIC RHINITIS; ANTIINFLAMMATORY ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ASTHMA; ATOPIC DERMATITIS; BINDING AFFINITY; BONE DENSITY; BURNING SENSATION; CANDIDIASIS; CATARACT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC RHINITIS; CONTACT ALLERGY; CONTACT SENSITIVITY; COUGHING; CUSHING SYNDROME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG MONITORING; DRUG PENETRATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRY NOSE; DYSPHONIA; EPISTAXIS; GROWTH DISORDER; GROWTH INHIBITION; HISTONE ACETYLATION; HOARSENESS; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERGLYCEMIA; HYPERPIGMENTATION; HYPERTRICHOSIS; HYPOPIGMENTATION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INFECTION; INTRAOCULAR HYPERTENSION; LUNG DISEASE; MILD PERSISTENT ASTHMA; MOOD CHANGE; MOON FACE; MYOPATHY; NASAL MUCOSAL ATROPHY; NONHUMAN; NOSE DISEASE; NOSE POLYP; NOSE SEPTUM PERFORATION; NOSE ULCER; OROPHARYNX CANDIDIASIS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT SATISFACTION; PERIORAL DERMATITIS; PHARYNGITIS; PYODERMA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ROSACEA; SIDE EFFECT; SKIN ATROPHY; SKIN BRUISING; SLEEP DISORDER; STINGING; SYSTEMATIC REVIEW (TOPIC); TELANGIECTASIA; THROAT IRRITATION; TINEA; TINEA INCOGNITO; TREATMENT DURATION; VOCAL CORD DISORDER; WEIGHT GAIN; CUTANEOUS DRUG ADMINISTRATION; INHALATIONAL DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, INHALATION; ADMINISTRATION, INTRANASAL; HUMANS; STEROIDS;

EID: 84971336943     PISSN: 15297322     EISSN: 15346315     Source Type: Journal    
DOI: 10.1007/s11882-016-0620-y     Document Type: Review

References (56)

1. Barnes P et al. How do corticosteroids work in asthma? Ann Intern Med. 2003;139:359–70.
2. Kovacs W et al. Metabolism of adrenal steroids. UptoDate.com. 2015.
3. Roland N, et al. The local side effects of inhaled corticosteroids. Current Understanding and Review of the Literature. Chest. 2004;126:213.
4. Hanania NA et al. Adverse effects of inhaled corticosteroids. Am J Med. 1995;98:196–208.
5. Held E et al. Perioral dermatitis in children under steroid inhalation therapy. Ugeskr Laeger. 1997;157:7002–3.
6. Derendorf H, Nave R, Drollmann A, Cerasoli F, Wurst W. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J. 2006;28(5):1042–50.
7. Kelly H, et al. Effect of inhaled glucocorticoids in childhood on adult height. New Engl J Med. 2012;367:904–912.
8. Kannisto S, et al. Adrenal suppression, evaluated by a low dose adrenocorticotropin test, and growth in asthmatic children treated with inhaled steroids. J Clin Endocrinol Metab. 1999;85:652–657.
9. Guilbert TW, et al. Growth of preschool children at high risk for asthma 2 years after discontinuation of fluticasone. JACI. 2011;128:956–963. e1–e7.
10. Skoner DP, et al. Effects of inhaled mometasone furoate on growth velocity and adrenal function: a placebo-controlled trial in children 4-9 years old with mild persistent asthma. J Asthma. 2011.48(8):848–59.
11. Scanlon PD et al. Lung Health Study Research Group. Loss of bone density with inhaled triamcinolone in Lung Health Study II. Am J Respir Crit Care Med. 2004;170:1302–9.
12. Wong CA, Walsh LJ, Smith CJP, et al. Inhaled corticosteroid use and bone mineral density in patients with asthma. Lancet. 2000;355(9213):1399–403.
13. Tattersfield AE et al. Bone mineral density in subjects with mild asthma randomised to treatment with inhaled corticosteroids or non-corticosteroid treatment for two years. Thorax. 2001;56(4):272–8.
14. Ip M et al. Decreased bone mineral density in premenopausal asthma patients receiving long term inhaled steroids. Chest. 1994;105(6):1722–7.
15. van Staa TP, Leufkens HG, Cooper C. Use of inhaled corticosteroids and risk of fractures. J Bone Miner Res. 2001;16:581–8.
16. Kuan YC, How SH, Azian AA, Liam CK, Ng TH, Fauzi AR. Bone mineral density in asthmatic patients on inhaled corticosteroids in a developing country. Ann Thorac Med. 2012;7(2):69–73.
17. Boulet LP, et al. Effects of long-term use of high-dose inhaled steroids on bone density and calcium metabolism. JACI. 1994;94(5):796–803.
18. Egan JJ et al. A randomized, double-blind study comparing the effects of beclomethasone and fluticasone on bonedensity over two years. Eur Respir J. 1999;13(6):1267–75.
19. Clark DJ, Clark RA, Lipworth BJ. Adrenal suppression with inhaled budesonide and fluticasone propionate given by a large volume spacer in asthmatic children. Thorax. 1996;51:941–3.
20. Clark DJ, Lipworth BJ. Adrenal suppression with chronic dosing of fluticasone propionate compared with budesonide in adult asthmatic patients. Thorax. 1997;52:55–8.
21. LoÈnnebo A, GrahneÂn A, Jansson B, Brundin RM, Ling-Andersson A, EckernaÈs S-AÊ. An assessment of the systemic activity of single and repeated doses of inhaled fluticasone propionate and inhaled budesonide in healthy volunteers. Eur J Clin Pharmacol. 1996;49:459–63.
22. Kowalski ML et al. Adrenal suppression by inhaled corticosteroids in patients with asthma: a systematic review and quantitative analysis. Allergy Asthma Proc. 2016;37:9–17. A large and current systematic review on inhaled steroids and cortisol suppression.
23. Hughes JA et al. One year prospective open study of the effect of high dose inhaled steroids, fluticasone propionate, and budesonide on bone markers and bone mineral density. Thorax. 1999;54(3):223–9.
24. Simons FE et al. Absence of posterior subcapsular cataracts in young patients treated with inhaled glucocorticoids. Lancet. 1993;342(8874):776–8.
25. Allen D. Systemic effects of intranasal steroids: an endocrinologists perspective. Suppl J Allergy Clin Immunol. 2000;106(4 Suppl):S179–90.
26. Sastre J, Mosges R. Local and systemic safety of intranasal corticosteroids. J Invest Allergy Clin Immunol. 2012;22(1):1–12.
27. Lund VJ, Preziosi P, Hercberg S, Hamoir M, Dubreuil C, Pessey JJ, et al. Yearly incidence of rhinitis, nasal bleeding, and other nasal symptoms in mature women. Rhinology. 2006;44:26–31.
28. Benninger MS et al. Techniques of intranasal steroid use. Otolaryngol Head Neck Surg. 2004;130:5–24.
29. Minshall E et al. Assessment by nasal biopsy of long-term use of mometasone furoate aqueous nasal spray (Nasonex) in the treatment of perennial rhinitis. Otolaryngol Head Neck Surg. 1998;118:648–54.
30. Zitt M, Kosoglou T, Hubbell J. Mometasone furoate nasal spray: a review of safety and systemic effects. Drug Saf. 2007;30:317–26.
31. Schenkel EJ et al. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics. 2000;105(2), E22.
32. Allen DB, Meltzer EO, Lemanske Jr RF, Philpot EE, Faris MA, Kral KM, et al. No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year. Allergy Asthma Proc. 2002;23:407–13.
33. Skoner DP, Rachelefsky GS, Meltzer EO, Chervinsky P, Morris RM, Seltzer JM, et al. Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate. Pediatrics. 2000;105:e23.
34. Lee DK, Robb FM, Sims EJ, Currie GP, McFarlane LC, Lipworth BJ. Systemic bioactivity of intranasal triamcinolone and mometasone in perennial allergic rhinitis. Br J Clin Pharmacol. 2003;55:310.
35. Giger R et al. Comparison of once- versus twice-daily use of beclomethasone dipropionate aqueous nasal spray in the treatment of allergic and non-allergic chronic rhinosinusitis. Eur Arch Otorhinolaryngol. 2003;260:135–40.
36. Moller C et al. Safety of nasal budesonide in the long-term treatment of children with perennial rhinitis. Clin Exp Allergy. 2003;33(6):816–22.
37. Teper A, Ratner PH. Mometasone furoate nasal spray is safe and effective for one-year treatment of children with perennial allergic rhinitis. J Allergy Clin Immunol. 2008;121 suppl 2:S52.
38. Oztürk F, Yücetürk AV, Kurt E, Unlü HH, Ilker SS. Evaluation of intraocular pressure and cataract formation following the long-term use of nasal corticosteroids. Ear Nose Throat J. 1998;10:846–8. 850-1.
39. Derby L, Maier WC. Risk of cataract among users of intranasal corticosteroids. J Allergy Clin Immunol. 2000;105:912–6.
40. Bui C, et al. Discontinuing nasal steroids might lower intraocular pressure in glaucoma. Am Acad Allergy Asthma Immunol. 2005;116(5):1042–7.
41. Ahmadi N et al. Intranasal corticosteroids do not affect intraocular pressure or lens opacity: a systematic review of controlled trials. Rhinology. 2015;53(4):290–302. Cohesive systematic review on intranasal steroids and pathology of ophthalmology.
42. Hengge U et al. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54:1–15.
43. Dey VK. Misuse of topical corticosteroids: a clinical study of adverse effects. Indian Dermatol Online J. 2014;5(4):436–40. Large population review on various adverse effects on topical steroids.
44. Coondoo A, Phiske M, Verma S, Lahiri K. Side-effects of topical steroids: a long overdue revisit. Indian Dermatol Online J. 2014;5(4):416–25. doi:10.4103/2229-5178.142483.
45. Thomson KF, Wilkinson SM, Powell S, Beck MH. The prevalence of corticosteroid allergy in two U.K. centres: prescribing implications. Br J Dermatol. 1999;141:863–6.
46. Wilkinson SM, Jones MF. Corticosteroid usage and binding to arginine: determinants of corticosteroid hypersensitivity. Br J Dermatol. 1996;135:225–30.
47. Coopman S, Degreef H, Dooms-Goossens A. Identification of cross-reaction patterns in allergic contact dermatitis from topical corticosteroids. The British Journal of Dermatology. 1989;121(1):27–34.
48. Fonacier L et al. Contact dermatitis: a practice parameter update 2015. J Allergy Clin Immunol Pract. 2015;3(3 Suppl):S1–39. Provides detailed overview on dermatitis and role of steroids.
49. Berth-Jones J. Topical therapy. In: Burns T, Breathnach S, Cox N, Griffiths C, editors. Rooks Textbook of Dermatology. 8th ed. 73., vol. 1. UK: Blackwell Science Ltd; 2010. p. 1–73.
50. Srinivas CR, Lakshmi C. Principles of topical therapy in dermatology. In: Valia RG, Valia AR, editors. IADVL Textbook of Dermatology, vol. 2. 3rd ed. Mumbai, India: Bhalani Publishing House; 2008. p. 1591–618.
51. Wolverton SE. Comprehensive Dermatologic Drug Therapy. 2nd ed. Philadelphia USA: Saunders Elsevier; 2007. Topical Corticosteroids; pp. 595–624.
52. Fisher DA. Adverse effects of topical corticosteroid use. West J Med. 1995;162:123–6.
53. Furue M, Terao H, Rikihisa W, Urabe K, Kinukawa N, Nose Y, et al. Clinical dose and adverse effects of topical steroids in daily management of atopic dermatitis. Br J Dermatol. 2003;148:128–33.
54. Olsen EA, Cornell RC. Topical clobetasol-17-propionate: review of its clinical efficacy and safety. J Am Acad Dermatol. 1986;15:246–55.
55. Ohman EM, Rogers S, Meenan FO, McKenna TJ. Adrenal suppression following low-dose topical clobetasol propionate. J R Soc Med. 1987;80:422–4. Erratum in: J R Soc Med 1988;81:308.
56. Ellison JA et al. Hypothalamic-pituitary-adrenal function and glucocorticoid sensitivity in atopic dermatitis. Pediatrics. 2000;105(4 Pt 1):794–9.